

Susan Lightman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/651521/publications.pdf>

Version: 2024-02-01

125
papers

5,488
citations

87401
40
h-index

100535
70
g-index

127
all docs

127
docs citations

127
times ranked

4080
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Infliximab in Disease Control of Refractory Orbital Myositis. Ocular Immunology and Inflammation, 2023, 31, 153-157.	1.0	1
2	Adhesion Molecule Targeted Therapy for Non-Infectious Uveitis. International Journal of Molecular Sciences, 2022, 23, 503.	1.8	6
3	Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis. Antibiotics, 2022, 11, 843.	1.5	3
4	Characteristic Needle-Shaped Pattern Seen on OCT in a Patient with Ocular Amyloidosis. Ophthalmology Retina, 2021, 5, 99-101.	1.2	5
5	Management of inflammatory choroidal neovascular membranes. Expert Review of Ophthalmology, 2021, 16, 47-60.	0.3	1
6	Small-molecule antagonist of VLA-4 (GW559090) attenuated neuro-inflammation by targeting Th17 cell trafficking across the blood-retinal barrier in experimental autoimmune uveitis. Journal of Neuroinflammation, 2021, 18, 49.	3.1	10
7	Learning points in intraocular lymphoma. Eye, 2021, 35, 1815-1817.	1.1	7
8	Intravitreal anti-vascular endothelial growth factor treatment for inflammatory choroidal neovascularization in non-infectious uveitis. American Journal of Ophthalmology, 2021, , .	1.7	0
9	CD4+ T-Cell Plasticity in Non-Infectious Retinal Inflammatory Disease. International Journal of Molecular Sciences, 2021, 22, 9584.	1.8	13
10	Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology, 2020, 127, 410-416.	2.5	23
11	The prognostic value of total macular external limiting membrane and ellipsoid zone damage for clinical outcome in treatment-resistant neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 2373-2378.	1.0	6
12	Prospective study of morphologic and functional parameter changes post intravitreal therapy for macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1941-1947.	1.0	2
13	Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical rimexolone 1%. International Ophthalmology, 2020, 40, 1061-1068.	0.6	2
14	Differentiating Multifocal Choroiditis and Punctate Inner Choroidopathy: A Cluster Analysis Approach. American Journal of Ophthalmology, 2020, 213, 244-251.	1.7	21
15	Vision loss in anterior uveitis. British Journal of Ophthalmology, 2020, 104, 1652-1657.	2.1	24
16	Recent Advances in Uveitis. , 2020, , 121-140.		1
17	I029–Acute anterior uveitis in spondyloarthropathies. Rheumatology, 2019, 58, .	0.9	0
18	Viral retinitis: diagnosis and management in the era of biologic immunosuppression: A review. Clinical and Experimental Ophthalmology, 2019, 47, 381-395.	1.3	23

#	ARTICLE	IF	CITATIONS
19	Re: Hughes etAl.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424). Ophthalmology, 2019, 126, e22-e24.	2.5	2
20	Using Local Therapy to Control Noninfectious Uveitis. Ophthalmology, 2018, 125, 329-331.	2.5	3
21	Comparing Treatment of Acute Retinal Necrosis With Either Oral Valacyclovir or Intravenous Acyclovir. American Journal of Ophthalmology, 2018, 188, 173-180.	1.7	48
22	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Ophthalmology, 2018, 125, 757-773.	2.5	178
23	â€“Statins in retinal diseaseâ€™. Eye, 2018, 32, 981-991.	1.1	21
24	Interobserver Agreement Among Uveitis Experts on Uveitic Diagnoses: The Standardization of Uveitis Nomenclature Experience. American Journal of Ophthalmology, 2018, 186, 19-24.	1.7	55
25	Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis. Clinical Ophthalmology, 2018, Volume 12, 2519-2534.	0.9	21
26	Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGIT. Frontiers in Immunology, 2018, 9, 907.	2.2	30
27	Longâ€“term effect of cataract phacoemulsification on the inflammation control and clinical outcome in uveitis patients[,]. Clinical and Experimental Ophthalmology, 2018, 46, 1048-1054.	1.3	10
28	Retinitis. , 2018, , 1533-1536.		0
29	A Review of Antimicrobial Therapy for Infectious Uveitis of the Posterior Segment. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2018, 7, 140-155.	0.4	12
30	Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. Autoimmunity Reviews, 2017, 16, 213-222.	2.5	28
31	Listeria Monocytogenes : a rare cause of endophthalmitis, a case report. IDCases, 2017, 8, 45-46.	0.4	9
32	Risk Factors for the Development of Cataract in Children with Uveitis. American Journal of Ophthalmology, 2017, 177, 139-143.	1.7	46
33	Clinical Outcome of Retinal Vasculitis and Predictors for Prognosis of Ischemic Retinal Vasculitis. American Journal of Ophthalmology, 2017, 177, 206-212.	1.7	24
34	Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis. Porto Biomedical Journal, 2017, 2, 33-39.	0.4	22
35	Aflibercept improves outcome in eyes with poor vision from neovascular ageâ€“related macular degeneration. Acta Ophthalmologica, 2017, 95, e342-e344.	0.6	1
36	Immunomodulatory Therapy in Uveitis. Developments in Ophthalmology, 2016, 55, 265-275.	0.1	6

#	ARTICLE	IF	CITATIONS
37	Intravitreal bevacizumab injections for diabetic macular edema – predictors of response: a retrospective study. Clinical Ophthalmology, 2016, Volume 10, 2093-2098.	0.9	9
38	A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept. Journal of Ophthalmology, 2016, 2016, 1-8.	0.6	43
39	Vogt–Koyanagi–Harada syndrome – current perspectives. Clinical Ophthalmology, 2016, Volume 10, 2345-2361.	0.9	55
40	Raised Intraocular Pressure in Nonjuvenile Idiopathic Arthritis-Uveitis Children: Risk Factors and Effect on Retinal Nerve Fiber Layer. Journal of Glaucoma, 2016, 25, 598-604.	0.8	4
41	Difference in glaucoma progression between the first and second eye after consecutive bilateral glaucoma surgery in patients with bilateral uveitic glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 2439-2448.	1.0	3
42	Non-Infectious Uveitis: Optimising the Therapeutic Response. Drugs, 2016, 76, 27-39.	4.9	21
43	Outcome of Treating Pediatric Uveitis With Dexamethasone Implants. American Journal of Ophthalmology, 2016, 161, 110-115.e2.	1.7	31
44	Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis. Ophthalmology, 2015, 122, 1262-1268.	2.5	53
45	Functional outcome of macular edema in different retinal disorders. Progress in Retinal and Eye Research, 2015, 48, 119-136.	7.3	28
46	Clinical and Imaging Features of Lacrimal Gland Involvement in Granulomatosis with Polyangiitis. Ophthalmology, 2015, 122, 2125-2129.	2.5	19
47	Tissue Interleukin-17 and Interleukin-23 as Biomarkers for Orbital Granulomatosis with Polyangiitis. Ophthalmology, 2015, 122, 2140-2142.	2.5	9
48	Treatment Strategies in Primary Vitreoretinal Lymphoma. JAMA Ophthalmology, 2015, 133, 191.	1.4	104
49	Adalimumab-induced remission of anterior scleritis: a very rare late manifestation of Takayasu arteritis: Fig. 1. Rheumatology, 2015, 54, kev324.	0.9	7
50	Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. American Journal of Ophthalmology, 2015, 160, 1133-1141.e9.	1.7	35
51	Outcome of Treatment of Uveitic Macular Edema. Ophthalmology, 2015, 122, 2351-2359.	2.5	77
52	The Role of Chorioretinal Biopsy in the Diagnosis of Intraocular Lymphoma. American Journal of Ophthalmology, 2015, 160, 1127-1132.e1.	1.7	35
53	Treatment of Uveitis with Intraocular Steroids. , 2015, , 81-90.	1	
54	Ischemic Retinal Vasculitis and Its Management. Journal of Ophthalmology, 2014, 2014, 1-13.	0.6	65

#	ARTICLE	IF	CITATIONS
55	Role of Autofluorescence in Inflammatory/Infective Diseases of the Retina and Choroid. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-9.	0.6	27
56	Long-Term Clinical Outcome and Causes of Vision Loss in Patients with Uveitis. <i>Ophthalmology</i> , 2014, 121, 2387-2392.	2.5	180
57	Long-term Clinical and Anatomic Outcome of Birdshot Chorioretinopathy. <i>JAMA Ophthalmology</i> , 2014, 132, 57.	1.4	50
58	Evaluation of Retinal Nerve Fiber Layer Thickness in Eyes With Hypertensive Uveitis. <i>JAMA Ophthalmology</i> , 2014, 132, 859.	1.4	23
59	The influence of diabetes mellitus on the management and visual outcome of patients with uveitis. <i>Acta Ophthalmologica</i> , 2014, 92, e329-30.	0.6	6
60	Primary intraocular lymphoma. <i>Survey of Ophthalmology</i> , 2014, 59, 503-516.	1.7	198
61	Clinical and Imaging Features Predictive of Orbital Granulomatosis with Polyangiitis and the Risk of Systemic Involvement. <i>Ophthalmology</i> , 2014, 121, 1304-1309.	2.5	52
62	The eye in virology. <i>International Journal of Ophthalmic Practice</i> , 2014, 5, 69-73.	0.0	0
63	Treatment with Repeat Dexamethasone Implants Results in Long-Term Disease Control in Eyes with Noninfectious Uveitis. <i>Ophthalmology</i> , 2014, 121, 1649-1654.	2.5	120
64	Outcomes of Changing Immunosuppressive Therapy after Treatment Failure in Patients with Noninfectious Uveitis. <i>Ophthalmology</i> , 2014, 121, 1119-1124.	2.5	23
65	Examining the Choroid in Ocular Inflammation: A Focus on Enhanced Depth Imaging. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-7.	0.6	163
66	The eye and phacomatoses: ocular and neuro-ophthalmic manifestations. <i>International Journal of Ophthalmic Practice</i> , 2014, 5, 53-57.	0.0	0
67	INTRAOCULAR METHOTREXATE CAN INDUCE EXTENDED REMISSION IN SOME PATIENTS IN NONINFECTIOUS UVEITIS. <i>Retina</i> , 2013, 33, 2149-2154.	1.0	75
68	Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. <i>Clinical Ophthalmology</i> , 2013, 7, 1109.	0.9	54
69	Should Intranasal Corticosteroids Be Used for the Treatment of Ocular Symptoms of Allergic Rhinoconjunctivitis? A Review of Their Efficacy and Safety Profile. <i>International Archives of Allergy and Immunology</i> , 2012, 158, 317-325.	0.9	24
70	Corticosteroid-Sparing Agents: New Treatment Options. <i>Developments in Ophthalmology</i> , 2012, 51, 47-56.	0.1	18
71	Dexamethasone Implant in Pediatric Uveitis. <i>Ophthalmology</i> , 2012, 119, 2412-2412.e2.	2.5	45
72	Topical Prostaglandin Analogues and Conjunctival Inflammation in Uveitic Glaucoma. <i>Open Ophthalmology Journal</i> , 2012, 6, 75-78.	0.1	8

#	ARTICLE	IF	CITATIONS
73	Histopathological features predictive of a clinical diagnosis of ophthalmic granulomatosis with polyangiitis (GPA). International Journal of Clinical and Experimental Pathology, 2012, 5, 684-9.	0.5	19
74	Intravitreal Triamcinolone Acetonide as Adjunctive Treatment with Systemic Therapy for Uveitic Macular Edema. European Journal of Ophthalmology, 2011, 21, 56-61.	0.7	32
75	Understanding uveitis: The impact of research on visual outcomes. Progress in Retinal and Eye Research, 2011, 30, 452-470.	7.3	272
76	Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis. JAMA Ophthalmology, 2011, 129, 545.	2.6	617
77	Review and update of intraocular therapy in noninfectious uveitis. Current Opinion in Ophthalmology, 2011, 22, 517-522.	1.3	37
78	Ocular manifestations of Wegener's granulomatosis. Expert Review of Ophthalmology, 2011, 6, 541-555.	0.3	7
79	New Developments in Corticosteroid Therapy for Uveitis. Ophthalmologica, 2010, 224, 46-53.	1.0	86
80	Periorbital corticosteroid injection in the management of uveitis in children. Acta Ophthalmologica, 2010, 88, e299-304.	0.6	25
81	Outcome of Raised Intraocular Pressure in Uveitic Eyes with and without a Corticosteroid-Induced Hypertensive Response. American Journal of Ophthalmology, 2009, 148, 207-213.e1.	1.7	62
82	Recent developments in the treatment of uveitis: an update. Expert Opinion on Investigational Drugs, 2009, 18, 609-616.	1.9	20
83	Short-term Safety and Efficacy of Intravitreal Triamcinolone Acetonide for Uveitic Macular Edema in Children. JAMA Ophthalmology, 2008, 126, 200.	2.6	54
84	Ocular manifestations of Wegener's granulomatosis. Expert Review of Ophthalmology, 2007, 2, 91-103.	0.3	4
85	Association between Heat Shock Protein 70/Hom Genetic Polymorphisms and Uveitis in Patients with Sarcoidosis. , 2007, 48, 3019.		50
86	Intraoperative use of intravitreal triamcinolone in uveitic eyes having cataract surgery: Pilot study. Journal of Cataract and Refractive Surgery, 2007, 33, 1278-1283.	0.7	37
87	Techniques that alter the concentration of intravitreal triamcinolone: author's reply. Acta Ophthalmologica, 2007, 85, 234-235.	0.4	0
88	Tomographic assessment of therapeutic response to uveitic macular oedema. Clinical and Experimental Ophthalmology, 2007, 35, 719-723.	1.3	43
89	Polymorphisms of chemokine and chemokine receptor genes in idiopathic immune-mediated posterior segment uveitis. Molecular Vision, 2007, 13, 388-96.	1.1	13
90	Endogenous Candida endophthalmitis. Expert Review of Anti-Infective Therapy, 2006, 4, 675-685.	2.0	50

#	ARTICLE	IF	CITATIONS
91	Cytokine gene polymorphisms involved in chronicity and complications of anterior uveitis. <i>Cytokine</i> , 2006, 35, 200-206.	1.4	14
92	Anti-TNF therapies in the management of acute and chronic uveitis. <i>Cytokine</i> , 2006, 33, 231-237.	1.4	83
93	Chemokine gene polymorphisms in idiopathic anterior uveitis. <i>Cytokine</i> , 2006, 35, 29-35.	1.4	22
94	Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy. <i>Clinical Immunology</i> , 2006, 121, 191-197.	1.4	6
95	Is IL-10 a Good Target to Inhibit Choroidal Neovascularisation in Age-Related Macular Disease?. <i>PLoS Medicine</i> , 2006, 3, e364.	3.9	2
96	Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. <i>Clinical and Experimental Ophthalmology</i> , 2005, 33, 16-21.	1.3	26
97	TNF α 857T, a Genetic Risk Marker for Acute Anterior Uveitis. , 2005, 46, 1565.		44
98	Emerging approaches to the treatment of uveitis: patents of 2000 – 2004. <i>Expert Opinion on Therapeutic Patents</i> , 2005, 15, 861-874.	2.4	3
99	Outcome of Intravitreal Triamcinolone in Uveitis. <i>Ophthalmology</i> , 2005, 112, 1916.e1-1916.e7.	2.5	196
100	Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. <i>Clinical and Experimental Ophthalmology</i> , 2004, 32, 563-568.	1.3	79
101	T-cell characterization in chronic allergic eye disease. <i>Current Allergy and Asthma Reports</i> , 2003, 3, 358-362.	2.4	2
102	Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. <i>Clinical and Experimental Ophthalmology</i> , 2003, 31, 487-491.	1.3	72
103	Diabetic retinopathy. <i>Clinical Cornerstone</i> , 2003, 5, 12-21.	1.0	65
104	Vitreous aspiration needle tap in the diagnosis of intraocular inflammation. <i>Ophthalmology</i> , 2003, 110, 595-599.	2.5	97
105	Cystoid macular edema in uveitis. <i>Ocular Immunology and Inflammation</i> , 2003, 11, 29-38.	1.0	59
106	Developments in the treatment of uveitis. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 59-67.	1.9	9
107	Use of methotrexate in the management of sight-threatening uveitis. <i>Ocular Immunology and Inflammation</i> , 2001, 9, 35-40.	1.0	49
108	Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. <i>Clinical and Experimental Ophthalmology</i> , 2001, 29, 2-6.	1.3	302

#	ARTICLE	IF	CITATIONS
109	Uveitis: what do we know and how does it help?. Clinical and Experimental Ophthalmology, 2001, 29, 48-51.	1.3	13
110	Pars planitis: a comparison of childhood onset and adult onset disease. Clinical and Experimental Ophthalmology, 2001, 29, 81-84.	1.3	42
111	The Potential of Newer Immunomodulating Drugs in the Treatment of Uveitis. BioDrugs, 2000, 13, 397-408.	2.2	13
112	Current and Novel Agents for the Treatment of Cytomegalovirus Retinitis. Drugs in R and D, 1999, 2, 289-297.	1.1	3
113	Mycophenolate mofetil. Ophthalmology, 1999, 106, 370-374.	2.5	151
114	An ultrastructural and systemic analysis of glycosaminoglycans in thyroid-associated ophthalmopathy. Eye, 1998, 12, 237-244.	1.1	45
115	New therapeutic options in uveitis. Eye, 1997, 11, 222-226.	1.1	22
116	Sympathetic Ophthalmia. International Ophthalmology Clinics, 1995, 35, 31-42.	0.3	13
117	Therapeutic Options in Ocular Allergic Disease. Drugs, 1995, 50, 208-221.	4.9	61
118	Systemic steroid prophylaxis for cataract surgery in patients with posterior uveitis. Ocular Immunology and Inflammation, 1994, 2, 207-216.	1.0	21
119	Vitreous fluid sampling and viral genome detection for the diagnosis of viral retinitis in patients with AIDS. Journal of Medical Virology, 1994, 43, 336-340.	2.5	97
120	The immunological features and pathophysiology of ocular cicatricial pemphigoid. Eye, 1994, 8, 196-199.	1.1	23
121	Visual prognosis in BehÃ§et's disease. Ocular Immunology and Inflammation, 1993, 1, 249-254.	1.0	14
122	Immunopathology and altered immunity in posterior uveitis in man: a review. Current Eye Research, 1992, 11, 11-15.	0.7	10
123	Aldose Reductase Messenger RNA in the Lens Epithelium <i>< i>in vivo</i></i> : Effects of Diabetes Mellitus and Galactosaemia. Clinical Science, 1990, 79, 599-603.	1.8	13
124	Immune mechanisms in chorido-retinal inflammation in man. Eye, 1990, 4, 345-353.	1.1	42
125	Basilar aneurysm an unusual cause of pain in a blind eye. Neuro-Ophthalmology, 1984, 4, 39-41.	0.4	17